* Patent covers treatment method for type 2 diabetes
* Also covers method to treat inflammatory diseases
* Shares jump 19 pct pre market
April 13 (Reuters) - Xoma Ltd (XOMA.O) said it received two new U.S. patents for methods of treating diabetes and inflammatory diseases using its anti-inflammatory antibody, sending its shares up 19 percent in pre-market trade.
One patent covers methods of treating type 2 diabetes, while the second covers methods of treating inflammatory diseases, including rheumatoid arthritis and osteoarthritis, with the antibody, XOMA 052.
The patents expire in 2027 and 2026, respectively, the biopharmaceutical company said in a statement.
Shares of the company were trading up 19 percent at 81 cents before the bell Tuesday. They closed at 68 cents Monday on Nasdaq. (Reporting by Anuradha Ramanathan in Bangalore; Editing by Vinu Pilakkott) ((email@example.com; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800: Reuters Messaging: firstname.lastname@example.org))